MedTrace Logo

Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less

NCT05193253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2022-01-18

No results posted yet for this study

Summary

Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for early-stage tumors. We sought to evaluate the oncologic outcomes of patients who received either RFA, LR, or LT as first-line treatment for solitary HCC ≤ 3cm in an intention-to-treat analysis.

Conditions

Interventions

PROCEDURE

Radiofrequency ablation

Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment

PROCEDURE

Liver resection

Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment

PROCEDURE

Liver transplantation

Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-01
Primary Completion
2018-11-30
Completion
2021-12-21

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193253 on ClinicalTrials.gov